POSEIDON Trial Phase 1b Results: Safety, Efficacy and Circulating Tumor DNA Response of the Beta Isoform-Sparing PI3K Inhibitor Taselisib (GDC-0032) Combined with Tamoxifen in Hormone Receptor Positive Metastatic Breast Cancer Patients
Baird, Richard D., van Rossum, Annelot G.J., Oliveira, Mafalda, Beelen, Karin, Gao, Meiling, Schrier, Mariette, Mandjes, Ingrid A.M., Garcia-Corbacho, Javier, Vallier, Anne-Laure, Dougall, Greig, vanVolume:
25
Journal:
Clinical Cancer Research
DOI:
10.1158/1078-0432.CCR-19-0508
Date:
November, 2019
File:
PDF, 730 KB
2019